Status:
COMPLETED
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
Lead Sponsor:
Fondazione Italiana Linfomi - ETS
Conditions:
Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognosti...
Eligibility Criteria
Inclusion
- Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT
- Age \>18 years
- Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR.
- Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion).
- Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up
- Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen.
- First IGEV course started before December 31st 2007
- Assessment of tumor response by Cheson 1999 criteria 11
Exclusion
- NONE
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
495 Patients enrolled
Trial Details
Trial ID
NCT01478191
Start Date
May 1 2010
End Date
June 1 2011
Last Update
March 6 2013
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Oncologico del Mediterraneo
Catania, Catania, Italy, 95029
2
Policlinico Maggiore
Milan, Italy, Italy, 20162
3
Ospedale San Gennaro
Napoli, Italy, Italy
4
Azienda Ospedaliera V. Cervello
Palermo, Italy, Italy, 90146